Clinical trials: Amlodipine
Renal Insufficiency, Chronic, Nephrotic Syndrome
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
Primary nephrotic syndrome(PNS) is a group of clinical symptoms caused by a variety of factors, including immune,environmental, genetic, et al.
- Trial name
- CKD (NCT02966717)
- Testing
- Rituximab, conventional therapy, Mesenchymal stem cells
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Zhujiang Hospital
Healthy
A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions
The purpose of this study to assess the single-dose relative bioavailability of Actavis Group hf and Pfizer (Norvasc®) 10 mg amlodipine besylate tablets, under fed conditions.
- Trial name
- NCT00870571
- Testing
- AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose, NorvasC® 10 mg Tablets
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Hypertension, Hyperhomocysteinemia
Feasibility Study of the Intensive Systolic Blood Pressure Control
The purpose of the current feasibility study is to test whether the blood pressure level of the study patients can be effectively and safely managed according to the intensive antihypertensive treatment protocol.
- Trial name
- NCT02817503
- Testing
- Standard BP control, Moderate BP control, Intensive BP control
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Hypertension
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine (EXforge®) with nifedipine, as well as vascular function index.
- Trial name
- EXAM (NCT01167153)
- Testing
- Valsartan/Amlodipine, Nifedipine
- Where
- China
- Volunteers
- 564 people
- Sponsor
- Novartis
Hypertension
Spironolactone Versus Indapamide in Obese and Hypertensive Patients
Most recent guidelines continue to recommend thiazide diuretics as first-line agents for patients with hypertension in spite of the potential metabolic side effects, while mineralocorticoid receptor antagonists (MRAs), such as…
- Trial name
- NCT03626506
- Testing
- Spironolactone, Indapamide, Amlodipine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University Third Hospital
Hypertension
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
Blood pressure in hypertensive patients is rarely controlled to an optimal level by one drug alone, often a combination of two or more drugs is essential to achieve a sufficient antihypertensive effect.
- Trial name
- NCT01286558
- Testing
- 40 mg telmisartan, 5 mg amlodipine, 80 mg telmisartan
- Where
- 8 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension, Dyslipidemias
Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
The purpose of this study is to evaluate the efficacy and safety of OLOMAX Tab (20/5/5mg, 20/5/10mg) in Hypertension Patients with Low-Intermediate Risk for Cardiovascular Disease.
- Trial name
- NCT04120753
- Testing
- OLOMAX 20/5/5mg, OLOMAX 20/5/10mg, Olmesartan 20 mg/Amlodipine 5 mg
- Where
- South Korea
- Volunteers
- 106 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.
- Trial name
- NCT01614366
- Testing
- AM 5 + DM 0, AM 5 + DM 2.5, AM 5 + DM 7.5
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- TSH Biopharm Corporation Limited
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00353912
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Novartis
Hypertension
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach…
- Trial name
- NCT02969265
- Testing
- Amlodipine, TCV-116CCB
- Where
- 25 sites in China
- Sponsor
- Takeda
HER2-negative Breast Cancer, Metastatic Breast Cancer
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced…
- Conditions
- HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05660083
- Testing
- L-NMMA
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- The Methodist Hospital Research Institute
Hypertension
To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets
An Open-label, Randomized, Single-dose, 2×2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets in Healthy Male…
- Trial name
- NCT02205151
- Testing
- Fimasartan, Amlodipine, Fimasartan/Amlodipine combination
- Where
- South Korea
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Arterial Hypertension, HTN
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of outpatients with arterial hypertension (HTN) initiated…
- Trial name
- TRIPTYCH (NCT06259175)
- Testing
- Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg, Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg, Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg
- Where
- Russia
- Volunteers
- 396 people
- Sponsor
- Servier Russia
Hypertension
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine…
- Trial name
- NCT00591266
- Testing
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Where
- 50 sites in United States
- Volunteers
- 566 people
- Sponsor
- Takeda
Hypertension
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight weeks compared with A5 (b) to demonstrate…
- Trial name
- NCT00558428
- Testing
- fixed dose combination of telmisartan+amlodipine, amlodipine
- Where
- 129 sites in Belgium, Canada and 10 more
- Volunteers
- 1,098 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Hypertension Control Based on Home Blood Pressure
The aim of this trial is to study the effects of antihypertensive therapy based on home systolic blood pressure (BP) with different target levels using two classes of drugs.
- Trial name
- NCT00198562
- Testing
- Amlodipine, Losartan
- Where
- Japan
- Volunteers
- 2,600 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Chronic Heart Failure
Effects of Amlodipine in the Management of Chronic Heart Failure
Patients with congestive heart failure are usually treated with a combination of an ACE inhibitor (or an AT1 blocking agent), a diuretic and a beta-blocker.
- Trial name
- NCT00151619
- Testing
- Amlodipine
- Where
- 2 sites in France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Hypertension
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety.
- Trial name
- NCT06618079
- Testing
- HUC2-565-A, HUC2-565-A and HUC2-565-B, HUC2-565-B, HUC2-565-A and HUC2-565-B
- Where
- South Korea
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of…
- Trial name
- NCT02569814
- Testing
- Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd